22 April 2022 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equivalent to Noxafil (posaconazole) Delayed-Release Tablets, 100 mg approved by the US Food and Drug Administration, the company said.

The Noxafil brand and generic had US sales of approximately USD 140.8m MAT for the most recent twelve months ending in February 2022 according to Iqvia.

Dr. Reddy's Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, focused on providing affordable medicines.

Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.